Home › Compare › CLIRF vs ABBV
CLIRF yields 1000000.00% · ABBV yields 3.06%● Live data
📍 CLIRF pulled ahead of the other in Year 1
Combined, CLIRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CLIRF + ABBV for your $10,000?
Clearford Water Systems Inc., a water management company, provides unified water infrastructure solutions in Canada, the United States, India, South America, and internationally. It operates in three segments: Waterworks, Water & Wastewater Infrastructure Delivery, and UV Pure Disinfection. The company offers Clearford One, a three-stage solution for wastewater servicing; ClearDigest, an on-site pre-treatment stage that removes solids at the source; ClearConvey, a network of small bore sewer pipes that carries liquids without any infiltration to an optimized facility for final treatment; and ClearRecover, a treatment facility. It also provides Clearford M-brane, a lifecycle solution for managed and decentralized water treatment; Clearford UV, which offers potable, wastewater, reuse, and rainwater disinfection systems; and Clearford Pay-for-Performance project financing program solutions. In addition, the company designs, manufactures, and sells ultraviolet purification systems using its patented Crossfire technology into the potable water, wastewater, reuse, and rainwater harvesting markets. Further, it provides water supply and wastewater treatment systems for small communities, as well as manufactures and supplies packaged treatment solutions, including containerized membrane plants for advanced water treatment. The company was formerly known as Clearford Industries Inc. and changed its name to Clearford Water Systems Inc. in June 2014. Clearford Water Systems Inc. is headquartered in Ottawa, Canada.
Full CLIRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.